Invented and developed by Neogenix, the antibody has shown anti-tumor effects for both pancreatic and colorectal tumors in both in-vitro and animal studies and may have both therapeutic and diagnostic applications.
Neogenix president and CEO Philip Arlen said that the patent is another major step for the company to move forward in their research for the diagnosis and treatment of a broad range of cancers.
"We believe that 16C3 has the potential to become an important addition to Neogenix’s new diagnostic and therapeutic tools in the fight against colorectal and pancreatic cancer," Arlen said.
"The antibody may have activity in other tumors as well, which the company will explore as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody."
The USPTO has previously granted patents for Neogenix’s monoclonal antibody NPC-1C (ensituximab) as well as its monoclonal antibody, 31.1.